<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Misra-Press, Anita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Quoix, Elisabeth</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TIME Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-13</style></pages><abstract><style  face="normal" font="default" size="100%">The phase 2b results of the randomized, double-blind, placebo-controlled TIME study provide evidence of activity with TG4010, a therapeutic cancer vaccine, when added to first-line chemotherapy for stage IV non–small cell lung cancer, especially for nonsquamous histology and low levels of triple-positive activated lymphocytes. These data suggest that normal levels of triple-positive activated lymphocytes may be a predictive biomarker of TG4010 efficacy.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>